Strategic Planning in the US Pharmaceutical Industry: An Introduction

Abstract

The history of strategic planning research as a foundation for the specific study of the strategic planning process in the US pharmaceutical industry is presented. A complete literature review is also provided. The economic variables that directly effect the US pharmaceutical industry: profitability, risk, research and development, promotion, federal regulation, and the generic drug sector of the drug industry are discussed. With this foundation, a short discussion of studies directly related to strategic planning in the US pharmaceutical industry and potential areas for future research are also suggested.

Keywords

US pharmaceutical industry Strategic planning Strategic planning process Environmental analysis Planning characteristics

Get full access to this article

View all access options for this article.

References

Steiner

Strategic planning, vii; George Steiner, Tomorrow's corporate planning and planners. Managerial Planning. 1972;20(5):1.

Trotter

Strategic planning theory and practice. Pace University, 1981; Ph.D. dissertation.

Ringbakk

Organized planning in major U.S. companies. Long Range Planning. 1969;2(2):46–57.

Hussey

The truth about corporate planning. London: Pergamon Press; 1983.

Glueck

Jauch

Business policy and strategic management, 4th ed. New York: McGraw-Hill; 1984.

Denning

Lehr

The extent and nature of corporate planning in the U.K.: Part 1. Journal of Management Studies. 1971;3(4):10–26.

Denning

Lehr

ME.

The extent and nature of corporate planning in the U.K.: Part 2. Journal of Management Studies. 1972;9(1):1–18.

Taylor

Irving

Organized planning in major U.K. companies. Long Range Planning. 1971;3(4):10–26.

Litschert

Some characteristics of long-range planning: An industry study. Academy of Management Journal. 1968;11(3):315–328.

10.

Kono

Long range planning — Japan — U.S.A. — A Comparative Study. Long Range Planning. 1976;9(5):61–71.

11.

Al-Bazzaz

Peter

How planning works in practice — A survey of 48 U.K. companies. Long Range Planning. 1980;13(4):30–42.

12.

Smith

Business strategy: An introduction. London: Basil Blackwell & Economist Publications; 1985.

13.

Brown

Sands

Thompson

GC.

Long range planning in the U.S.A.-NICB. Long Range Planning. 1969;1(3):44–51.

14.

Aug

Chua

Long range planning in large United States corporations. Long Range Planning. 1979;12(3):99–102.

15.

Ansoff

Avener

Brandenburg

Does planning pay? The effect of planning on success and acquisition in American firms. Long Range Planning. 1970;3(2):2–7.

16.

Thune

House

Where long range planning pays off. Business Horizons. 1970;13:81–87.

17.

Kudla

Strategic planning and risk. Review of Business & Economic Research. 1981;17(1):2–14.

18.

Leontiades

Tezel

Planning perceptions and planning results. Strategic Management Journal. 1980;1(1):65–70.

19.

Greenly

Does strategic planning improve company performance?

Long Range Planning. 1986;19(2):101–109.

20.

Malik

Karger

Does long range planning improve company performance?

Management Review. 1975;64(9):27–31.

21.

Ringbakk

Why planning fails. European Business (Spring 1971).

22.

Steiner

Pitfalls in comprehensive long range planning. Oxford, OH: Planning Executives Institute; 1972.

23.

Steiner

Schollhammer

Pitfalls of multinational long-range planning. Long Range Planning. 1975;8(2):2–7.

24.

Shetty

YK.

New look at corporate goals. California Management Review. 1979;22(2):74.

25.

Alexander

LD.

Successfully implementing strategic decisions. Long Range Planning. 1985;18(3):91–97.

26.

Stiwenius

Planning for a rapidly changing environment in SAS. Long Range Planning. 1985;18(2):22–29.

27.

Engledow

Lenz

RT.

Whatever happened to environmental analysis. Long Range Planning. 1985;18(2):93–106.

28.

Derkinderen

Crum

Pitfalls in using portfolio techniques — Assessing risks and potential. Long Range Planning. 1984;17(2):129–136.

29.

Jain

Environmental scanning in U.S. corporations. Long Range Planning. 1984;17(2):117–128.

30.

Fahey

King

Environmental scanning for corporate planning. Business Horizons. 1977;20(4):61–71.

31.

Diffenbach

Corporate environmental analysis in large corporations. Long Range Planning. 1983;16(3):107–116.

32.

Porter

Competitive strategy. New York: The Free Press; 1980.

33.

Byars

The strategic management process: A model & terminology. Managerial Planning. 1984;32(6):38–44.

34.

Hansen

The pharmaceutical development process: Estimates of current development costs and times and the effect of regulatory changes. In: Chien

Robert I.

, ed. Issues in Pharmaceutical Economics. Lexington, MA: D.C. Heath; 1979:151–181.

35.

Conrad

Plotkin

Risk/return: U.S. industry pattern. Harvard Business Review. 1968;46:90–99.

36.

Annual Survey Report PMA 1987–1989. Washington, D.C: Pharmaceutical Manufacturers Association, pp 3–33.

37.

Schartzman

Innovation in the pharmaceutical industry. Baltimore: Johns Hopkins University Press; 1976.

38.

Research & development in industry. Washington, D.C: National Science Foundation; 1982.

39.

Leffler

Persuasion or information? The economics of prescription drug advertising. Journal of Law & Economics. 1981;24(1):52.

40.

Egan

Higginbothan

Weston

Economics of the pharmaceutical industry. New York: Praeger, 1982.

41.

Comanor

The political economy of the pharmaceutical industry. Journal of Economic Literature. 1986;24(3):1196.

42.

PMAs 25 Largest Members Are Spending 20% of Annual Sales for Drug Research and Development, Rep.

Waxman's Staff Reports on Drug Prices Finds. FDC Reports. 1987;49(17):8–10.

43.

Pradhan

International pharmaceutical marketing. Westport, CT: Quorum Books; 1983.

44.

Walton

Ad recognition and prescribing by physicians. Journal of Advertising Research. 1980;20(3):46.

45.

Comanor

Wilson

Competition in the pharmaceutical industry. In: Chien

R. I.

ed. Issues in Pharmaceutical Economics. Lexington, MA: D.C. Heath, 1979.

46.

Cooper

Prices and profits in the pharmaceutical industry. London: Pergamon Press; 1966.

47.

Hutt

Morrison

Abbreviated new drug applications. Washington, D.C: Law & Business, Inc./Harcourt Brace Jovanovich, Publisher; 1985.

48.

Generic ANDA Deluge Set Off by Waxman Law , Drug & Cosmetic Industry. 1985;136(1):42–45.

49.

Predicasts Forecasts. 1989; Cleveland, OH., p. B255.